Overview
| 别名 | Scinderin; Adseverin |
| 基因名 | SCIN |
| UniProt ID | Q9Y6U3 |
| 反应种属 | Human |
| 应用 | WB,IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 5T5-L2-T3 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 80 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:1000; IHC-1:200-1:250 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Scinderin (SCIN), also known as adseverin, is a calcium-dependent actin-severing and capping protein belonging to the gelsolin superfamily, predominantly expressed in secretory tissues where it regulates cortical actin networks and facilitates vesicle movement during secretion by severing actin filaments in response to increased intracellular calcium. SCIN plays a critical role in actin cytoskeletal organization, osteoclastogenesis, and the regulation of chondrocyte proliferation and differentiation, influencing cellular processes such as cell proliferation and differentiation through pathways involving MAPK and p38 signaling. Functionally, SCIN inhibits cell proliferation and tumorigenesis, and its overexpression has been shown to downregulate cyclin A1 and phosphorylated STAT3, thereby promoting cell cycle arrest at the S/G2 phase and suppressing oncogenic signaling. Clinically, altered SCIN expression is associated with various cancers, where reduced SCIN levels can predict poor prognosis and increased tumor cell proliferation. |
检测原理